| Code | CSB-RA011664MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Vamikibart, targeting interleukin-6 (IL-6), a pleiotropic cytokine that plays a central role in immune regulation and inflammatory responses. IL-6 is produced by various cell types including T cells, macrophages, and fibroblasts, and mediates its effects through both classical and trans-signaling pathways. Elevated IL-6 levels are implicated in numerous pathological conditions, including rheumatoid arthritis, cytokine release syndrome, systemic juvenile idiopathic arthritis, and various autoimmune disorders. The cytokine also contributes to the acute phase response and has been associated with chronic inflammatory states and certain malignancies.
Vamikibart is a therapeutic monoclonal antibody designed to neutralize IL-6 activity by binding to the cytokine and preventing its interaction with cellular receptors. This biosimilar antibody serves as a valuable research tool for investigating IL-6-mediated signaling pathways, studying inflammatory disease mechanisms, and evaluating potential therapeutic interventions targeting the IL-6 axis. It enables researchers to explore cytokine biology and immune modulation in various experimental models.
There are currently no reviews for this product.